Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15.
Published October 15, 2025 · Recall initiated: September 16, 2025
Summary
FDA records drug Class II recall D-0006-2026, published October 15, 2025 and initiated September 16, 2025. Recalling firm: ACCORD HEALTHCARE, INC.; Status: Ongoing; Reported quantity: 54,432 bottles; Lot: Lot # D2300045, Exp 12/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
What to do
Voluntary: Firm initiated · Letter
Get an email if LEVOTHYROXINE SODIUM has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- ACCORD HEALTHCARE, INC.
- Distributor
- Nationwide in the US
- UPC
- 0316729447157
- Lot
- Lot # D2300045, Exp 12/31/2025.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDALevothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDALevothyroxine Sodium Tablets, USP, 300 mcg (0.3 mg), 90-count bottles, Rx Only, Manufactured for: AccordSeptember 2, 2026
- FDAAFCO, Hand Sanitizer (Isopropyl Alcohol-Based, Product 5515), Manufactured by: AFCO, 550 Development Avenue,October 15, 2025
- FDANorgestimate and Ethinyl Estradiol Tablets, USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, 3October 15, 2025
Questions about this recall
Was Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-450-15. recalled?
Yes. FDA published recall D-0006-2026 on October 15, 2025. Reported hazard: Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: LEVOTHYROXINE SODIUM. UPC: 0316729447157.